Computerized Guideline in Heart Failure: Implementation Process and Impact Evaluation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

13008 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-11-30

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective: To assess the effectiveness of implementation process of an electronic Heart Failure guideline in primary care in the city of Barcelona.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Design: Two types of design will be applied, according to the specific aims. On the one hand it is a cross-sectional and a qualitative study, on the other hand it is quasi-experimental study. Pre-post intervention with a control group, as well as, of repeated measures in the intervention group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Heart Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

chronic heart failure Computerized clinical guidelines Primary care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 control group

Computerized data collection of outcome measures in usual care

No interventions assigned to this group

2 intervention group

Computerized data collection of outcome measures and interviews to clinicians which are using a computerized Heart Failure guideline in their daily practice.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* general and nurse primary care practitioners working in Barcelona and Girona for the Health Catalan Institute.
* Managers involved in implementation process for the computerised clinical guideline in Barcelona from the Health Catalan Institute.
* patients with diagnoses of Heart Failure according to ICD-10 according to general practice clinical records.

Exclusion Criteria

* Managers and general and nurse primary care practitioners working in Barcelona health Centres where there were any other quality improvement project related to Heart failure at the time of the intervention which we are evaluating. Managers from the control group (Girona).
* patients with a mental health disorder or terminal illness

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Josep M Davins, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Unitat de Suport a la Recerca, Barcelona, Spain

Eva Frigola, Masters

Role: STUDY_DIRECTOR

Unitat de Suport a la Recerca, Barcelona, Spain

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Unitat de Suport a la Recerca

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI07/91020

Identifier Type: -

Identifier Source: org_study_id